SANUWAVE Health, Inc. has reported a significant decline in its financial performance for the third quarter of 2026, with revenues falling by 24% compared to the previous year. This downturn highlights ongoing challenges within the surgical and medical instruments sector, particularly in the wound care market.
On November 10, 2026, SANUWAVE announced its financial results for the quarter ending September 30, 2026. The company, which specializes in FDA-cleared wound care products, reported revenues of $8.6 million, down from $11.3 million in the same quarter last year. This decrease is attributed to a reduction in the sales of its Ultramist® systems, which dropped to 40 units sold in Q3 2026 from 155 in Q3 2025.
Founded in Nevada, SANUWAVE Health operates under the Standard Industrial Classification (SIC) code 3841, which encompasses Surgical & Medical Instruments & Apparatus. The company trades on the Nasdaq under the ticker SNWV. Recent filings include an 8-K on November 10, 2026, detailing these financial results, and a 10-Q for the same period.
According to the filing, the gross margin for Q3 2026 was reported at 77.3%, slightly down from 77.6% in Q3 2025. The company also experienced an operating loss of $1.1 million, contrasting with an operating income of $0.9 million in the same quarter last year. The net loss for the quarter was $1.4 million, a stark contrast to a net income of $9.7 million in Q3 2025, largely due to a lack of one-time gains that had benefited the prior year's results.
CEO Morgan Frank commented on the challenges faced during the quarter, linking them to proposed changes by the Centers for Medicare & Medicaid Services (CMS) that affected pricing and market dynamics. He noted, "Q3 was very much the story of the CMS proposed rule, which affected Sanuwave in multiple ways." The proposed maintenance of skin substitute pricing at 2026 levels for 2027 led to some mobile wound care practitioners exiting the market, impacting SANUWAVE's customer base.
The filing does not specify what actions SANUWAVE may take next in response to these results, but the upcoming conference call scheduled for November 11, 2026, at 8:30 AM EST may provide further insights. Investors and industry observers will be keen to hear how the company plans to navigate these challenges moving forward.
As SANUWAVE grapples with these financial hurdles, other companies in the surgical and medical instruments sector may also feel the ripple effects. The current market environment poses significant challenges for all players, and strategic adjustments may be necessary to adapt to the changing landscape.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










